Multiple Sclerosis
Largest, most representative MS premium dataset available for licensing, analytics, and collaboration.
Research-Grade RWD in MS
Unmet Need
Disease with no cure
With no cure for MS, early diagnosis and effective treatment are the best ways to help reduce damaging effects and improve patients’ quality of life.
Deep Clinical Data
20,100+*
MS patients in the OM1 PremiOM™ MS Dataset followed prospectively with deep clinical, lab, and other linked data
* Counts complete through Q2 2023
Analytics & Modeling
535,000+*
MS patients in the OM1 Real-World Data Cloud that can be used for modeling, analysis, and other research purposes
Why OM1 MS?
Sample Use Cases
» Feasibility |
» Comparative Effectiveness |
» Passive Safety |
» Natural History |
Publication
Read our peer reviewed publication:
Infosheet
Learn about PremiOM™MS:
- Poster (CNS Summit 2021): Assessing Comorbid Behavioral Health Conditions, Healthcare Resource Utilization, and Medication Use in Patients Seeking Mental Health Care within a Large, Representative Real-World Multiple Sclerosis Registry
- Publication (May 2021): Treatment patterns following initiation of generic glatiramer acetate among patients with multiple sclerosis from two large real-world databases in the United States
- Poster (ICPE September 2020): Comparison of Symptoms, Treatments, and Healthcare Resource Utilization in Patients with Multiple Sclerosis by Sex in a Real-World Cohort in the U.S.
- Poster (AAN 2020): A Real-World Retrospective Analysis of Outcomes in Multiple Sclerosis Patients Who Transitioned to Alemtuzumab After Rituximab or Ocrelizumab
- Poster (ACTRIMS Forum 2020): Treatment Patterns and Reasons for Switching among US Patients with Multiple Sclerosis Taking the Glatiramer Acetate Class of Products
- Poster (ICPE 2019): Predicting Relapse Episodes in Patients with Multiple Sclerosis Treated with Disease Modifying Therapies in a Large Representative US-Based Real World Cohort
- Poster (ICPE 2019): Revisiting MS Prevalence in the 21st Century: Exploration Based on a Large Representative US-Based Real World Cohort
- Poster (AAN 2019): Real-World Switching Patterns Among US Generic Glatiramer Acetate Multiple Sclerosis Patients
WEBINAR: Using real-world data to amplify disability scores in Multiple Sclerosis patients
View webinar to learn more.